Navigation Links
InspireMD Provides Corporate Update, Plans for 2012
Date:1/23/2012

ries: Germany, Hungary, Israel, Poland, Canada, Czech Republic, France, the Netherlands, Ireland, Serbia, Brazil and South Africa. It is actively enrolling patients in 32 centers. The trial's principal investigators are Prof. Alexandre Abizaid, Prof. Dariusz Dudek and Prof. Sigmund Silber. Detailed results from the trial are expected to be submitted for presentations at interventional cardiology meetings in the second half of the year.

Plans for U.S. Registration of MGuard™ Underway

InspireMD is advancing its regulatory strategy for U.S. FDA approval for MGuard™ with a trial that is scheduled to begin in the second half of 2012. This trial will consist of patients undergoing primary revascularization for Acute Myocardial Infarction (AMI) who will be randomized to undergo PCI (Percutaneous Coronary Intervention) with either the MGuard Prime System or the comparator Abbott Vision BMS stent.

The primary efficacy endpoint will be a myocardial blush score of 3, with a successful outcome based on superiority of MGuard™ to the BMS stent. The primary safety endpoint will be non-inferiority Target Vessel Failure (TVF) with secondary endpoints including ST-segment resolution at 60 minutes and MACE at 30 days, 6 and 12 months. Dr. Donald Cutlip, Executive Director of Clinical Investigation at the Harvard Clinical Research Institute, will provide scientific leadership of the FDA Registration trial.

2011 Preliminary Shipment and Revenue Results

Unaudited preliminary shipments of the MGuard™ Coronary Stent system for 2011 increased approximately 78% compared to 2010. Unaudited preliminary revenues for 2011 were approximately $6.0 million, compared to $4.9 million in 2010, an increase of approximately 21%. These numbers have not yet been audited by PWC, InspireMD's external auditors. Final audited numbers for the year will be announced when the Company reports year-end 2011 earnings in March.  <
'/>"/>

SOURCE InspireMD
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
2. For the First Time, at EuroPCR, InspireMD Will Provide a Sneak Preview of the Next Generation MGuard Prime(R), a State of the Art Net Protective Cobalt Chromium Stent System
3. InspireMD Becomes a Supporting Organization in the Growing Stent for Life Initiative
4. InspireMD Boosts MGuard Production Capacity
5. InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR"
6. InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference
7. InspireMD Increases Geographic Penetration; MGuard Stent is Now Available in India
8. InspireMD Promotes MGuard™ at the EuroPCR 2011 Exhibition and Conference in Paris This Week
9. InspireMD Announces Year-to-Date 2011 Progress
10. InspireMD Broadens Global Distribution Network; Signs Distributor for the Russian Federation
11. Sol J. Barer, Ph.D. Joins InspireMD Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... THOUSAND OAKS, Calif. , May 22, ... today announced the Company has commenced termination ... commercialization of brodalumab with AstraZeneca (LON:AZN, STO:AZN ... investigational IL-17 inhibitor, is in development for ... and axial spondyloarthritis.  The decision was based ...
(Date:5/22/2015)... May 22, 2015 The Assistance Fund announces ... program provides financial assistance for copay to individuals diagnosed ... announce the addition of the Melanoma Copay Assistance Program ... McGreevy , executive director. "With each additional program we ... a world where no one is denied access to ...
(Date:5/22/2015)... May 22, 2015  The U.S. Food and ... -- the first biosimilar product approved in ... toward growth in the contract manufacturing organization (CMO) ... industry is geared to the production of small-molecular ... biopharmaceutical products. The healthcare market research publisher,s report, ...
Breaking Medicine Technology:Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5The Assistance Fund Adds Melanoma Assistance Program 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... April 26, 2012 Upsher-Smith Laboratories, Inc. ( ... the pharmacokinetic (PK) profile of USL255, its once-daily, ... 64th Annual American Academy of Neurology (AAN) Meeting.  ... USL255 and equal doses of immediate-release (IR) topiramate ...
... effects of Neupro ® (rotigotine transdermal system) on ... today at the 64th AAN Annual Meeting in New ... data from five, randomized, double-blind,  placebo-controlled trials investigated the ... fatigue in patients with PD. Improvements were observed with ...
Cached Medicine Technology:Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 2Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 3Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 4Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate 5New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 2New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 3New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 4New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 5New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 6New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 7New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 8New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 9New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinson's disease 10
(Date:5/24/2015)... NY (PRWEB) May 24, 2015 The ... Sunday, May 24th in San Diego at Petco Park. ... North America. On May 20th, they had a warmup ... At their preview show in Los Angeles, this beloved band ... they also played fan favorites such as "Jumping Jack Flash," ...
(Date:5/24/2015)... Scientists with Cardno ChemRisk, a scientific consulting firm, ... that may have raised the risk of mesothelioma for ... an article on the research. Click here to ... asbestos levels well above OSHA safety guidelines when they ... “Asbestos compliance sampling data associated with the construction, automotive ...
(Date:5/24/2015)... 24, 2015 Indiana Fiber Network, LLC ... Midwest Telecom of America, Inc. (MTA) has selected IFN ... Cory Childs, IFN Enterprise Sales Manager, fiber route diversity ... “IFN’s fiber transport provides MTA with the diverse fiber ... Tier 1 Internet and voice carriers located at Henry ...
(Date:5/23/2015)... 2015 On Saturday, May 23, 2015, over ... for Branches Florida City exactly five years to the day ... 2010. , A large fire tore through the Branches United ... 2010 in the middle of the night as neighbors, staff ... declared arson even though it is suspected that the fire ...
(Date:5/23/2015)... York, NY (PRWEB) May 23, 2015 ... announced that, “the company has been the target ... as a part of the company’s ongoing Information Technology ... on health insurers.” , The most notable attack ... year when Anthem Inc., the nation’s second largest health ...
Breaking Medicine News(10 mins):Health News:The Rolling Stones Tickets in San Diego, Orlando, Minneapolis, Dallas, Pittsburgh, Indianapolis, Atlanta, Detroit, Milwaukee, Kansas City, Columbus, Nashville & Raleigh 2Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4
... Medicare Strike Force Since March, WASHINGTON, Oct. 4 ... and operator of Direct Nursing Assistance Inc. of,Medicare fraud, ... and U.S. Attorney R. Alexander Acosta of the Southern ... trial, Rodolfo Aenlle, 47, was found guilty on all,counts ...
... IRIDEX,Corporation (Nasdaq: IRIX ) announced the ... the Company,s new independent auditor effective October,2, 2007. ... by the Audit Committee of the Company,s Board ... discussions with several,public accounting firms. BPM replaces PricewaterhouseCoopers ...
... in September Proving Successful, OWINGS MILLS, Md., Oct. ... that based on the current business outlook, the,Company is ... 31,2007. The Company expects to report revenue of $81 ... per diluted share. Previously, the Company,expected to report revenue ...
... part of what is ... nonprofit for teens., WILSONVILLE, Ore., Oct. 4 On Tuesday, October ... furniture,arcade games and supplies. These and other items, unused for at least ... the,Sexual Minority Youth Resource Center (SMYRC). Volunteer crews will move an ...
... Oct. 4 - A new American Heart,Association survey (1) shows consumer awareness ... an all-time high. But consumers still need,some key information to improve how ... the Bad Fats Are The survey shows that:, --While 92 ... jump from 84 percent in 2006 - only 21 percent ...
... revealing how toxic chemicals disrupt gene activity and other ... -- and why some individuals are particularly vulnerable. For ... more likely to experience side effects from certain medications, ... , How can this type of research -- known ...
Cached Medicine News:Health News:Miami Jury Convicts Medical Company Owner of Medicare Fraud 2Health News:Medifast Announces Updated Full Year 2007 Guidance 2Health News:Medifast Announces Updated Full Year 2007 Guidance 3Health News:Medifast Announces Updated Full Year 2007 Guidance 4Health News:Contents of the McGinnis Mansion Refurbishes Portland, Oregon Sexual Minority Youth Center 2Health News:Contents of the McGinnis Mansion Refurbishes Portland, Oregon Sexual Minority Youth Center 3Health News:Americans' Knowledge of Fats Growing But Still Insufficient 2Health News:Americans' Knowledge of Fats Growing But Still Insufficient 3
RapidStrep A test is a qualitative test that detects group A,streptococcal antigen. The test is a rapid, in vitro assay. It is,intended for professional use to help diagnose Strep A,infection i...
... caused by the intracellular parasite Toxoplasma gondii ... or by contract with cat,feces containing oocytes. ... be passed to the fetus through the ... is a cause of mortality and malformation.,This ...
... an immunochromatographic in vitro assay,for detection ... infection.,Infectious mononucleosis (IM) is caused by ... is based on detection of,serum antibodies ... the,heterophile antibodies present in the sera ...
Inquire...
Medicine Products: